Addressing the universal desire to heal and be well

Addressing the universal desire to heal and be well

The costs of mental illness, addiction, and trauma are too high.

We need new solutions that bridge tradition to innovation to help individuals and communities find meaning and connect.

Numinus is building those solutions, by creating an integrated ecosystem centred around the delivery of safe, evidence-based, accessible psychedelic-assisted psychotherapy.

We are in this for the long run and the right reasons.

Licensed by Health Canada to produce and extract psilocybin from mushrooms

Numinus is at the forefront of addressing the growing prevalence of mental health issues and desire for greater wellness.

Numinus has received Health Canada approval to amend the Company’s existing licence under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms. The amendment means Numinus is the first publicly traded company in Canada to be granted a licence by Health Canada to conduct research of this kind.

With this regulatory approval, Numinus is able to proceed with the production of naturally sourced, sustainable psilocybin for research purposes that will support the emerging field of psychedelic-assisted psychotherapy and research, at lower costs to currently produced synthetic psilocybin. The licence also allows Numinus to develop and licence its own exclusive IP for further product development in partnership with leading research organizations — something the research community has been seeking to secure.

The company’s existing licence (in alignment with licence holder Salvation Botanicals Ltd) allows Numinus to test, possess, buy and sell MDMA, psilocybin, psilocin, DMT, and mescaline.

Numinus is dedicated to providing access to therapies that enhance and supplement existing options. Psychedelics will be part of this but will only be available for treatment once approved by regulators and governing bodies.

Transformative change is needed

971 million

People worldwide currently suffering from a mental disorder

450,000

People worldwide died from drug use in 2015

1 in 2

Canadians affected by mental health issues by the age of 40

4,000

Canadians dying by suicide per year – almost 11 suicides per day

1 in 2

Canadians experiencing a depressive episode receive inadequate care

1 in 5

Canadians suffering from addiction in any given year

1 in 11

Canadian adults will suffer PTSD in their lifetime

$51B

Estimated annual economic burden of mental illness in Canada

Investors